VC: Anthera gets $36M in VC



Anthera gets $36M in VC

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Anthera Pharmaceuticals
San Francisco

$36M
Second

Venture Partners and Sofinnova Ventures

The funding will be used for the clinical development of its newly-licensed anti-inflammatory compounds.

Addex Pharmaceuticals
Switzerland

$32M
Third

SR One

The funding will be used to develop Addex's clinical and pre-clinical drug candidates.

Alvine Pharmaceuticals
Palo Alto, CA

$21M
First

Sofinnova Ventures

Alvine is developing a treatment for celiac sprue.

ActoGenix
Belgium

$15M
Round

GIMV and Life Sciences Partners

The financing will allow ActoGeniX to initiate development of a pipeline of therapeutic products based on its TopAct technology platform.

NuPathe
Conshohocken, PA

$15M
First

Birchmere Ventures

The financing will support NuPathe's clinical programs related to therapeutic products to treat migraine and other CNS disorders.

Pepscan Systems
Netherlands

$9M
Second

BioX Biosciences

The funds will be used to continue and expand development of its existing portfolio of therapeutic vaccines programs.

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.